1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. ResApp Health Limited
  6. News
  7. Summary
    RAP   AU000000RAP5

RESAPP HEALTH LIMITED

(RAP)
  Report
Delayed Australian Stock Exchange  -  02:10 2022-08-15 am EDT
0.1850 AUD    0.00%
08/06RESAPP HEALTH : Pfizer raises scheme consideration to A$0.208 per share
PU
07/22RESAPP HEALTH : Study shows efficacy of ResAppDx use with masks
PU
07/21ResApp Health Validates Effectivity of Respiratory Diagnostic App in Mask-Wearing Patients; Shares Fall 4%
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

ResApp Health : receives FDA 510(k) clearance for SleepCheckRx

07/05/2022 | 07:54pm EDT

View printer-friendly version

Brisbane, Australia, 6 July 2022 - ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, is pleased to announce that SleepCheckRx has received 510(k) clearance as a prescription-only software-as-a-medical device from the US Food and Drug Administration (FDA). Gaining FDA clearance enables ResApp to commercially market the test in the United States.

SleepCheckRx is an easy to use, at-home sleep test that screens adults for the risk of moderate to severe obstructive sleep apnoea by analysing breathing and snore sounds recorded on an Apple iPhone. It requires no accessories or hardware other than an iPhone to make an assessment. ResApp plans to solicit 510(k) clearance for Android devices in the future.

Sleep apnoea is the most common sleep breathing disorder and affects more than three in every ten men and nearly two in every ten women1. Obstructive sleep apnoea is when air stops flowing to the lungs during sleep. The prevalence of sleep apnoea is increasing due to an ageing population and increasing rates of obesity. Studies have shown that up to 80% of people with sleep apnoea are undiagnosed and untreated2.

SleepCheckRx will be made available to patients via a prescription from their healthcare provider. Patients will be provided with a specific code allowing them to download SleepCheckRx from the App Store, with their results uploaded to a healthcare provider portal.

In an at-home clinical trial of 220 patients comparing SleepCheckRx to simultaneous polysomnography, the SleepCheckRx algorithms correctly identified 89.3% of patients with moderate to severe obstructive sleep apnoea (AHI greater than or equal to 15/hour) and achieved a specificity of 77.6%.

Tony Keating, CEO and Managing Director said: "We are delighted to have secured FDA clearance for SleepCheckRx. With more than 20 million American adults suffering from sleep apnoea and the majority of those not knowing that they have the condition, this clearance unlocks a significant market opportunity for ResApp. By using SleepCheckRx, physicians will have the opportunity to screen their patients conveniently and quickly for sleep apnoea, helping their patients take the first step to getting treatment."

1. Peppard et al., Increasing prevalence of sleep-disordered breathing in adults, Am J Epidemiol 177(9), 2013
2. Frost & Sullivan, Hidden Health Crisis Costing America Billions

###

About ResApp Health Limited

ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease. ResApp's machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. ResApp's regulatory-approved and clinically validated products include ResAppDx, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department and primary care settings; and SleepCheck, a smartphone application which allows consumers to self-assess their risk of sleep apnoea. Both products are CE Marked in Europe and TGA approved in Australia. For more information, please visit www.resapphealth.com.au.

Disclaimer

ResApp Health Limited published this content on 06 July 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 05 July 2022 23:53:04 UTC.


© Publicnow 2022
All news about RESAPP HEALTH LIMITED
08/06RESAPP HEALTH : Pfizer raises scheme consideration to A$0.208 per share
PU
07/22RESAPP HEALTH : Study shows efficacy of ResAppDx use with masks
PU
07/21ResApp Health Validates Effectivity of Respiratory Diagnostic App in Mask-Wearing Patie..
MT
07/20RESAPP HEALTH : Clarification - Scheme Booklet registered with ASIC
PU
07/17RESAPP HEALTH : Scheme Booklet registered with ASIC
PU
07/15ResApp Health Secures Court Orders for Scheme Deal
MT
07/08ResApp Health Agrees to One-Year Extension of Commercial License Deal
MT
07/06ResApp Health Limited Agrees to 12 Month Extension to its Commercial Licence Agreement ..
CI
07/06ResApp Health Secures US FDA Medical Device Clearance for Sleep Apnea Software
MT
07/05RESAPP HEALTH : Cough detection patent granted in Australia and Japan
PU
More news
Financials
Sales 2021 0,07  - -
Net income 2021 -6,77 M - -
Net cash 2021 6,40 M - -
P/E ratio 2021 -4,71x
Yield 2021 -
Capitalization 159 M 113 M -
EV / Sales 2020 -
EV / Sales 2021 413 455 192x
Nbr of Employees 510
Free-Float 81,0%
Chart RESAPP HEALTH LIMITED
Duration : Period :
ResApp Health Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RESAPP HEALTH LIMITED
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Managers and Directors
Tony Keating Chief Executive Officer, Executive Director & MD
Al Rey Lunar Vice President-Finance
Roger Aston Non-Executive Chairman
Christopher Ntoumenopoulos Non-Executive Director
Brian Leedman Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
RESAPP HEALTH LIMITED184.62%113
SNAP INC.-75.29%19 161
KAKAO GAMES CORP.-35.49%3 514
ANGI INC.-42.67%2 657
DENA CO., LTD.3.56%1 613
FINVOLUTION GROUP-4.26%1 346